Allosteric modulators of 5-hydroxytryptamine 2C receptor (5-HT2CR)

US9533973B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9533973-B2
Application numberUS-201214363141-A
CountryUS
Kind codeB2
Filing dateDec 7, 2012
Priority dateDec 8, 2011
Publication dateJan 3, 2017
Grant dateJan 3, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The disclosure is directed to compounds identified as allosteric modulators of 5-HT 2CR, as well as pharmaceutical compositions and methods using the same. Certain embodiments also include methods of identifying and methods of synthesizing the compounds. Optimization and development of allosteric 5-HT 2CR modulators that bind sites other than the primary ligand binding site generate novel, highly selective, and potent ligands of 5-HT2CR. Such molecules can be used as small molecule probes for the nervous system and as effective therapeutics for a variety of diseases.

First claim

Opening claim text (preview).

The invention claimed is: 1. A compound having the general formula of Formula I wherein, Y is —NH; Z is a linear or branched C 1 , C 2 , C 3 , or C 4 , alkyl; R 1 is hydroxy, or hydroxy substituted C 1-4 alkyl; R 2 is hydrogen, hydroxy, or hydroxy substituted C 1-4 alkyl; X is a linear, saturated C 10-15 alkyl; and R 3 is hydrogen, methyl, or ethyl. 2. The compound of claim 1 , wherein R 1 is a hydroxy substituted C 1 alkyl. 3. The compound of claim 1 , wherein R 2 is hydroxy. 4. The compound of claim 1 , wherein the compound is (2,4-cis-4-undecyl-piperidine-2-carboxylic acid (2,3-dihydroxypropyl)amide); or (2,4-cis-4-undecyl-piperidine-2-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)amide).

Assignees

Inventors

Classifications

  • by oxygen atoms · CPC title

  • Lincomycin; Derivatives thereof · CPC title

  • Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title

  • C07D405/12Primary

    linked by a chain containing hetero atoms as chain links · CPC title

  • Oxygen atoms · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9533973B2 cover?
The disclosure is directed to compounds identified as allosteric modulators of 5-HT 2CR, as well as pharmaceutical compositions and methods using the same. Certain embodiments also include methods of identifying and methods of synthesizing the compounds. Optimization and development of allosteric 5-HT 2CR modulators that bind sites other than the primary ligand binding site generate novel, high…
Who is the assignee on this patent?
Univ Texas
What technology area does this patent fall under?
Primary CPC classification C07D405/12. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jan 03 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).